Physician profile
Bora Lim
NPI 1134317548
$48,974.30
in general payments reported to CMS, 2019-2025
19 companies · $15K in 2025
The $15K reported for 2025 was more than what 85% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,909 · 2020: $43.27 · 2021: $11.92 · 2022: $3,582 · 2023: $9,338 · 2024: $11K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $34K · Food and Beverage: $920 · Travel and Lodging: $216 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $34,267.68 |
| Food and Beverage | $919.77 |
| Travel and Lodging | $215.53 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $31,025.62 | 2021-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $9,136.56 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $4,733.05 | 2019-2022 | |
| Daiichi Sankyo INC. | $1,541.82 | 2024-2025 | Enhertu |
| Lilly USA, LLC | $1,050.00 | 2019 | |
| Eli Lilly and Company | $859.18 | 2022-2024 | |
| Pfizer INC. | $142.34 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $114.68 | 2019 | |
| Celgene Corporation | $87.80 | 2019 | |
| Immunitybio, INC. | $83.48 | 2025 | |
| Puma Biotechnology, INC. | $73.35 | 2019 | |
| Stemline Therapeutics INC. | $61.33 | 2025 | Orserdu |
| Genentech USA, INC. | $46.49 | 2024 | |
| Hologic INC | $18.60 | 2022 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bora Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.